Patents by Inventor Maria I. Nunez

Maria I. Nunez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TUSC2 therapies
    Patent number: 9675663
    Abstract: A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: June 13, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack Roth, David Stewart, Charles Lu, Ignacio I. Wistuba, Shaoyu Yan, Maria I. Nunez
  • TUSC2 THERAPIES
    Publication number: 20160310569
    Abstract: A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
    Type: Application
    Filed: July 11, 2016
    Publication date: October 27, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jack ROTH, David STEWART, Charles LU, Ignacio I. WISTUBA, Shaoyu YAN, Maria I. NUNEZ
  • TUSC2 THERAPIES
    Publication number: 20150297631
    Abstract: A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 22, 2015
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jack ROTH, David STEWART, Charles LU, Ignacio I. WISTUBA, Shaoyu YAN, Maria I. NUNEZ
  • TUSC2 THERAPIES
    Publication number: 20140377339
    Abstract: A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jack ROTH, David STEWART, Charles LU, Ignacio I. WISTUBA, Shaoyu YAN, Maria I. NUNEZ
  • TUSC2 THERAPIES
    Publication number: 20120244209
    Abstract: A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 27, 2012
    Inventors: Jack A. Roth, David Stewart, Charles Lu, Ignacio I. Wistuba, Shaoyu Yan, Maria I. Nunez